

Author (year)	Tumor volume (ml)	Max diameter (mm)	Margin dose (Gy)	Isodose (%)	Max dose (Gy)	Total dose (Gy)	Dose (Gy)/Fractionation
Unger <i>et al.</i> (2002)	3.8 (0.02-27.22)		12 Gy (9-18Gy)	30-80%			
Iwai <i>et al.</i> (2003)	3.6 (0.7-24.9)		12 Gy (8-12)				
Myrseth <i>et al.</i> (2005)			12.2 Gy (10-20)		35.3 Gy (17-40)		
Hempel <i>et al.</i> (2006)	1.6 (0.1-9.9)		13 Gy (10-14.5)	40-85%	22.7 (15.6-32.5)		
Liu <i>et al.</i> (2006)	10.8 (0.11-27.8)		12.3 (10-14)		24.9 (21-30)		
Chopra <i>et al.</i> (2007)	1.3 (0.08-37.5)		13 (12-13)	50-65	26 (20-26)		
Fukuoka <i>et al.</i> (2009)	2.0 (0.1-18.6)		12.0 (9-15)		24 (17.1-30)		
Pollock <i>et al.</i> (2009)	2.9		13 (12-14)		28 (24-30)		
Nagano <i>et al.</i> (2010)	2.5 (0.1-13.2)		12.0 (10.5-13.0)	50 (50-67)			
Roos <i>et al.</i> (2011)		22 (11-40)	12 (12-14)				
Sun <i>et al.</i> (2012)	3.6 (0.3-27.3)		13.0 (6.0-14.4)	45 (20-68)	28.0 (15.0-60.0)		
Yomo <i>et al.</i> (2012)	0.73 (0.03-5.37)		12.1 (9-14)	51.1 (40-80)			
Hasegawa <i>et al.</i> (2013)	2.8 (0.07-36.7)		12.8 (10-18)	50 (40-95)	25 (13-36)		
Kim <i>et al.</i> (2013)	0.34 (0.03-1.00)		12.2 (11.5-13.0)	51 (50-70)	24.3 (17.1-26.2)		
Boari <i>et al.</i> (2014)	1.2 (0.013-14.3)		13 (11-15)	50 (40-63)	26 (20-32.6)		
Mindermann <i>et al.</i> (2014)	1.85		12.9	50	25.8		
Wangerid <i>et al.</i> (2014)	1.65 (0.1-8.4)		12.3 (11-16)	50-60	26 (17-47)		
Aoyama <i>et al.</i> (2012)		20 (7-48)		80-90		50 (30-50)	2 (1.8-2)*
Litre <i>et al.</i> (2013)	2.7 (1.5-15.5)					50	1.8

Dose schedules of the studies included in the analysis. Values are reported as median or mean (range).

* 7 of 201 patients in *Aoyama et al.* recieved a hypofractionated treatment regime.